ALLMedicine™ Myasthenia Gravis Center

Oct 19th, 2020 - Muscle weakness related to myasthenia gravis (MG) limits the daily functioning of patients. MG patients often experience subjective symptoms including psychiatric disorders, fatigue, and reduction in self-efficacy. All of which ultimately influenc...

Oct 17th, 2020 - Little is known about how different outlier estimation methods affect cut-off limits for outliers in single fiber electromyography. We compared in a prospective fashion the established 18th -jitter value (18th jv) method to three, whole-distributi...

Oct 17th, 2020 - Myasthenia gravis (MG) is an autoantibody-mediated disease of the neuromuscular junction. The neuromuscular junction damage associated with MG is caused by anti-acetylcholine receptor (AChR) antibody and complements. Recently, eculizumab (an anti-...

Oct 16th, 2020 - This study is aimed at exploring the expression pattern and methylation level of G0S2 in the peripheral blood mononuclear cells (PBMCs) of myasthenia gravis (MG) patients with positive acetylcholine receptor (AChR) autoantibodies and revealing the...

Oct 13th, 2020 - Autoimmune polyglandular syndrome (APS) is a rare disease that is characterized by autoimmune reactions to multiple endocrine and non-endocrine organs, which can be divided into four main types. The principal manifestations of APS-3 are autoimmune...

Nov 9th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

Jun 30th, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

Apr 20th, 2010 - Important progress has been made in our understanding of the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) and neuromyotonia (Isaacs' syndrome). To prepare consensus guideli...

Sep 17th, 2008 - Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, ...

Soliris® is a first-in-class terminal complement inhibitor discovered, developed, and commercialized by Alexion. Soliris® works by inhibiting terminal complement, a part of the immune system that, when activated in an uncontrolled manner, plays a...

Oct 19th, 2020 - Muscle weakness related to myasthenia gravis (MG) limits the daily functioning of patients. MG patients often experience subjective symptoms including psychiatric disorders, fatigue, and reduction in self-efficacy. All of which ultimately influenc...

Oct 17th, 2020 - Little is known about how different outlier estimation methods affect cut-off limits for outliers in single fiber electromyography. We compared in a prospective fashion the established 18th -jitter value (18th jv) method to three, whole-distributi...

Oct 17th, 2020 - Myasthenia gravis (MG) is an autoantibody-mediated disease of the neuromuscular junction. The neuromuscular junction damage associated with MG is caused by anti-acetylcholine receptor (AChR) antibody and complements. Recently, eculizumab (an anti-...

Oct 16th, 2020 - This study is aimed at exploring the expression pattern and methylation level of G0S2 in the peripheral blood mononuclear cells (PBMCs) of myasthenia gravis (MG) patients with positive acetylcholine receptor (AChR) autoantibodies and revealing the...

Oct 13th, 2020 - Autoimmune polyglandular syndrome (APS) is a rare disease that is characterized by autoimmune reactions to multiple endocrine and non-endocrine organs, which can be divided into four main types. The principal manifestations of APS-3 are autoimmune...

Feb 19th, 2020 - The complement C5 inhibitor zilucoplan significantly improved muscle weakness and daily functioning in patients with moderate to severe generalized myasthenia gravis (gMG), according to investigators who conducted a phase 2, randomized, placebo-co.

Oct 29th, 2019 - AUSTIN, TEX. – When testing for acetylcholine receptor (AChR) autoantibodies in patients with suspected myasthenia gravis, testing for binding antibodies and for modulating antibodies is more accurate than testing for either subtype alone, researc.

Oct 18th, 2019 - AUSTIN, TEX. – Patients with suspected myasthenia gravis are more likely to have positive repetitive nerve stimulation (RNS) findings if they undergo testing in an inpatient setting, are seropositive, or are classified as Myasthenia Gravis Foundat.

Oct 17th, 2019 - AUSTIN, TEX. – Neurologists consider influenza vaccination to be safe in most patients with autoimmune neuromuscular disorders such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP), according to a survey presented.

Oct 17th, 2019 - Suggestions from the data The post hoc subgroup analysis should be interpreted with caution, and the study does not provide firm conclusions, Dr. Nowak noted.